BioPharma Resources

Drug Trial Radar · NCT07890454

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Dec 28, 2027

Study completion Dec 28, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01

Conditions

  • Immunization
  • Healthy Volunteers
  • COVID-19 Immunization
  • Influenza Immunization

Interventions

  • IIV-HD (standalone)Drug

    Pharmaceutical form: Suspension Route of administration: Intramuscular injection

  • NVXC19 (EU licensed, standalone)Drug

    Pharmaceutical form: Dispersion Route of administration: Intramuscular injection

  • IIV-HD + NVXC19 combinationDrug

    Pharmaceutical form: Suspension Route of administration: Intramuscular injection

  • Placebo, normal salineDrug

    Pharmaceutical form: Solution Route of administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antibody titers against for each of the 3 influenza vaccine strains(in a subset of participants)Time frame: At Day 28 after vaccination
  2. Antibody titers against SARS-CoV-2 specific variant(in a subset of participants)Time frame: At Day 28 after vaccination

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 6160002

    Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting

  • Investigational Site Number : 6160020

    Gdynia, Pomeranian Voivodeship, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.